Wechselwirkungen · Zolsketil pegylated liposomal
ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-146351 · Präparat HOS-099502
No formal medicinal product interaction studies have been performed with doxorubicin pegylated liposomal, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride. Doxorubicin pegylated liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxorubicin hydrochloride (HOS-085564) mercaptopurine (HOS-085568) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-16T15:10:00Z · SHA-256 749f25cb02ef3c2557fff9c44c8608815445daccd9aad038fce4e840c7fa1845 · Passage 0b9d37625b16db4ecf52c2fb81330158395a656841966e8e2e651e80dc4f39ee · Zeichen 0–1019 im Abschnitt